Lucira Health, Inc. (LHDXQ) SEC Filing 8-K Material Event for the period ending Tuesday, September 19, 2023

Lucira Health, Inc.

CIK: 1652724 Ticker: LHDXQ

View differences made from one to another to evaluate Lucira Health, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Lucira Health, Inc..


Assess how Lucira Health, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Lucira Health, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Lucira Health, Inc. provided additional information to their SEC Filing as exhibits

Ticker: LHDXQ
CIK: 1652724
Form Type: 8-K Corporate News
Accession Number: 0001193125-23-241312
Submitted to the SEC: Mon Sep 25 2023 4:01:01 PM EST
Accepted by the SEC: Mon Sep 25 2023
Period: Tuesday, September 19, 2023
Industry: In Vitro And In Vivo Diagnostic Substances
  1. Bankruptcy or Receivership
  2. Event for Officers
  3. Financial Exhibit
  4. Other Events
  5. Security Holders Change

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: